Skip to main content

Anifrolumab Improves Lupus Outcomes

Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).

305 severe SLE patients received either intravenous ANIFR (300 mg, 1000 mg) or placebo (PBO) every 4 weeks for 48 weeks. Patients were stratified by disease activity, steroid dose and high vs. low IFN gene expresssion. The primary endpoint was a composite of SRI(4) response at day 169 with sustained reduction of oral steroids (10mg/day).

ANIFR-treated patients met the primary endpoint at Day 169 moreso than PBO patients (PBO: 17.6%; 300 mg: 34.3%, p=0.014; 1000 mg: 28.8%, p=0.063).

After 1 year, the SRI endpoint was met by 25.5% of PBO, 51.5% of 300 mg (p0.001) and 38.5% of 1000 mg (p=0.048) patients. Steroid reduction to ≤7.5 mg/day was achieved by 26.6% of PBO, 56.4% of 300 mg (p=0.001) and 31.7% of 1000 mg (p=0.595) patients.

ANIFR demonstrated consistent benefit across multiple global and organ-specific measures at Day 365. 75% of patients were IFN high at baseline. The ANIFR efficacy was similar or better in IFN high patients and this was associated with suppression of IFN-regulated genes ~90% for both doses of ANIFR.

Serious adverse events were reported in 18.8% of patients on PBO and 16.7% of patients in the pooled ANIFR groups.

A higher frequency of influenza and Herpes zoster (PBO: 2.0%; 300 mg: 5.1%; 1000 mg: 9.5%) occurred with ANIFR treatment.

Anifrolumab reduced disease activity in SLE. These data with the enhanced effects in IFN high patients support the pathobiology of this treatment strategy. 

Join The Discussion

Donald E Thomas Jr

| Nov 10, 2015 1:51 pm

Thanks for this information.. I hope the phase 3 trials are as successful. btw... I believe the correct spelling (for the title) should be "anifrolumab."

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject